Vifor Pharma AG
SIX:VIFN
Vifor Pharma AG
Pre-Tax Income
Vifor Pharma AG
Pre-Tax Income Peer Comparison
Competitive Pre-Tax Income Analysis
Latest Figures & CAGR of Competitors
Company | Pre-Tax Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
V
|
Vifor Pharma AG
SIX:VIFN
|
Pre-Tax Income
CHf311.7m
|
CAGR 3-Years
5%
|
CAGR 5-Years
7%
|
CAGR 10-Years
0%
|
Novartis AG
SIX:NOVN
|
Pre-Tax Income
$12.3B
|
CAGR 3-Years
8%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
1%
|
|
NLS Pharmaceutics AG
NASDAQ:NLSP
|
Pre-Tax Income
-$16.5m
|
CAGR 3-Years
-45%
|
CAGR 5-Years
-20%
|
CAGR 10-Years
N/A
|
|
Roche Holding AG
SIX:ROG
|
Pre-Tax Income
CHf14.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
0%
|
CAGR 10-Years
0%
|
|
S
|
Sandoz Group AG
SIX:SDZ
|
Pre-Tax Income
$1.1B
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
See Also
What is Vifor Pharma AG's Pre-Tax Income?
Pre-Tax Income
311.7m
CHF
Based on the financial report for Dec 31, 2021, Vifor Pharma AG's Pre-Tax Income amounts to 311.7m CHF.
What is Vifor Pharma AG's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
0%
Over the last year, the Pre-Tax Income growth was 18%. The average annual Pre-Tax Income growth rates for Vifor Pharma AG have been 5% over the past three years , 7% over the past five years .